ChitogenX Inc. (CHNXF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 3.84 Million CAD | -22.2% |
| 2023 | 4.93 Million CAD | 11.6% |
| 2022 | 4.42 Million CAD | 63.51% |
| 2021 | 2.7 Million CAD | -1.56% |
| 2020 | 2.74 Million CAD | 360.01% |
| 2019 | 597.38 Thousand CAD | 2.92% |
| 2018 | 580.41 Thousand CAD | -59.96% |
| 2017 | 1.44 Million CAD | 456.86% |
| 2016 | -406.24 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 3.09 Million CAD | -35.16% |
| 2024 Q3 | 2.93 Million CAD | -5.16% |
| 2024 Q4 | 3.84 Million CAD | 30.7% |
| 2024 FY | 3.84 Million CAD | -22.2% |
| 2024 Q1 | 4.77 Million CAD | -3.2% |
| 2023 Q1 | 3.45 Million CAD | -21.98% |
| 2023 Q3 | 5.97 Million CAD | 21.49% |
| 2023 Q4 | 4.93 Million CAD | -17.32% |
| 2023 FY | 4.93 Million CAD | 11.6% |
| 2023 Q2 | 4.91 Million CAD | 42.39% |
| 2022 Q2 | 3.66 Million CAD | 19.24% |
| 2022 Q4 | 4.42 Million CAD | -0.29% |
| 2022 FY | 4.42 Million CAD | 63.51% |
| 2022 Q1 | 3.07 Million CAD | 37.39% |
| 2022 Q3 | 4.43 Million CAD | 21.1% |
| 2021 Q1 | 3.09 Million CAD | 34.07% |
| 2021 FY | 2.7 Million CAD | -1.56% |
| 2021 Q3 | 2.47 Million CAD | -24.47% |
| 2021 Q4 | 2.23 Million CAD | -9.58% |
| 2021 Q2 | 3.27 Million CAD | 5.85% |
| 2020 Q4 | 2.3 Million CAD | 14.72% |
| 2020 FY | 2.74 Million CAD | 360.01% |
| 2020 Q3 | 2.01 Million CAD | 39.46% |
| 2020 Q1 | 1.08 Million CAD | 71.16% |
| 2020 Q2 | 1.44 Million CAD | 33.52% |
| 2019 Q1 | 1.08 Million CAD | 62.56% |
| 2019 Q2 | 1899.00 CAD | -99.83% |
| 2019 Q3 | 458.72 Thousand CAD | 24056.29% |
| 2019 Q4 | 631 Thousand CAD | 37.55% |
| 2019 FY | 597.38 Thousand CAD | 2.92% |
| 2018 Q3 | 52.57 Thousand CAD | -85.67% |
| 2018 FY | 580.41 Thousand CAD | -59.96% |
| 2018 Q2 | 366.97 Thousand CAD | 89.72% |
| 2018 Q1 | 193.42 Thousand CAD | -77.83% |
| 2018 Q4 | 669.46 Thousand CAD | 1173.4% |
| 2017 Q1 | 258 Thousand CAD | 163.51% |
| 2017 Q2 | 508.1 Thousand CAD | 96.93% |
| 2017 Q4 | 872.48 Thousand CAD | 64.43% |
| 2017 Q3 | 530.62 Thousand CAD | 4.43% |
| 2017 FY | 1.44 Million CAD | 456.86% |
| 2016 FY | -406.24 Thousand CAD | 0.0% |
| 2016 Q4 | -406.24 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 75.639% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 6.751% |
| SQZ Biotechnologies Company | -36.23 Million USD | 110.597% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 91.027% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 160.909% |
| Mesoblast Limited | 55.85 Million USD | 93.125% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -314.156% |
| Genus plc | 190.6 Million USD | 97.985% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -71.748% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -216.339% |
| Marizyme, Inc. | 18.56 Million USD | 79.32% |
| ContraFect Corporation | -6.02 Million USD | 163.724% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -464.706% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -2752.071% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -232.344% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -71.258% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 30.206% |
| MultiCell Technologies, Inc. | 90.04 USD | -4264671.213% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 623.176% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 70.338% |
| EV Biologics, Inc. | 1.36 Million USD | -180.708% |
| Q BioMed Inc. | 4.06 Million USD | 5.419% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 87.432% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -517.002% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -281.06% |
| Biomind Labs Inc. | 711.4 Thousand USD | -439.779% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 96.503% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 70.015% |
| Skye Bioscience, Inc. | -5.72 Million USD | 167.117% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -346.387% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -2646.703% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 32.016% |
| IMV Inc. | 7.67 Million USD | 49.938% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -19228.535% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -74.388% |
| GB Sciences, Inc. | 1.74 Million USD | -119.766% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 2189.364% |
| HST Global, Inc. | 96.79 Thousand USD | -3867.229% |
| CSL Limited | 10.52 Billion USD | 99.964% |
| Halberd Corporation | 144.72 Thousand USD | -2553.381% |
| Enzolytics Inc. | 981.65 Thousand USD | -291.176% |
| Resverlogix Corp. | 6.45 Million USD | 40.474% |
| Affymax, Inc. | -5.59 Million USD | 168.608% |
| SYBLEU INC | 473.71 Thousand USD | -710.616% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 670.504% |
| argenx SE | -2.02 Billion USD | 100.189% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 91.159% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 108.168% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -41.77% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 143.439% |
| AVAX Technologies, Inc. | -5.9 Million USD | 165.049% |
| Zenith Capital Corp. | 10.06 Thousand USD | -38055.803% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.362% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -1815.862% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -60.937% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -2234.219% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 93.658% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -92.058% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 249.414% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -967.527% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 81.061% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 21062.987% |
| BioStem Technologies, Inc. | 4.47 Million USD | 14.133% |
| ONE Bio Corp. | 9.04 Million USD | 57.522% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -1808.037% |
| Burzynski Research Institute, Inc. | -1310.00 USD | 293229.771% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -1762.116% |
| Agentix Corp. | 37.63 Thousand USD | -10104.353% |
| LadRx Corporation | -2.03 Million USD | 288.562% |
| Cell Source, Inc. | 9.23 Million USD | 58.405% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 18916.151% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -504.565% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -504.565% |
| NovAccess Global Inc. | 2.17 Million USD | -76.271% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 45.693% |
| Itoco Inc. | 228.3 Thousand USD | -1581.961% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -2723.758% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 22.534% |
| Kadimastem Ltd | -253.1 Thousand USD | 1617.175% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -855.583% |
| CytoDyn Inc. | 20.26 Million USD | 81.048% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 593608.501% |
| Mobile Lads Corp. | 484.23 Thousand USD | -693.008% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 41531.367% |
| Qrons Inc. | 351.42 Thousand USD | -992.688% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 50.169% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 1638.338% |
| Rebus Holdings, Inc. | 305 Thousand USD | -1159.016% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 13.844% |
| International Stem Cell Corporation | 2.59 Million USD | -48.263% |
| Bioxytran, Inc. | 1.89 Million USD | -102.221% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -6052.564% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -76.074% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -11.823% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 55.103% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -397.019% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 407.2% |
| Neutra Corp. | 52.18 Thousand USD | -7258.154% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 254.279% |
| PureTech Health plc | -167.19 Million USD | 102.297% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 1667.936% |
| IXICO plc | -4.44 Million USD | 186.397% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 70.951% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 92.999% |
| CSL Limited | 10.52 Billion USD | 99.964% |
| Cellectis S.A. | -43.81 Million USD | 108.763% |